← Back to Screener
BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT)
Price$9.26
Favorite Metrics
Price vs S&P 500 (26W)-29.64%
Price vs S&P 500 (4W)-1.77%
Market Capitalization$748.31M
P/E Ratio (Annual)98.47x
All Metrics
Book Value / Share (Quarterly)$8.05
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.05
Price vs S&P 500 (YTD)-29.46%
EPS (TTM)$0.20
10-Day Avg Trading Volume0.48M
EPS Excl Extra (TTM)$0.20
EPS (Annual)$0.36
ROI (Annual)4.03%
Cash / Share (Quarterly)$0.03
P/E Basic Excl Extra (TTM)158.63x
P/E Normalized (Annual)98.47x
ROA (Last FY)3.91%
EBITD / Share (TTM)$-0.18
Cash Flow / Share (Annual)$-0.03
P/B Ratio3.95x
P/B Ratio (Quarterly)1.32x
ROA (TTM)2.42%
EPS Growth QoQ (YoY)-58.45%
EPS Incl Extra (Annual)$0.36
Current Ratio (Annual)10.40x
Quick Ratio (Quarterly)0.25x
3-Month Avg Trading Volume0.28M
P/E Incl Extra (TTM)158.63x
52-Week High$14.87
EPS Excl Extra (Annual)$0.36
26-Week Price Return-20.90%
Quick Ratio (Annual)9.05x
13-Week Price Return-22.34%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.33x
Enterprise Value$747.643
Cash / Share (Annual)$0.07
3-Month Return Std Dev68.84%
ROE (Last FY)4.03%
EPS Basic Excl Extra (Annual)$0.36
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.20
ROI (TTM)2.51%
Revenue / Share (Annual)$0.00
P/E Ratio (TTM)158.63x
EPS Growth TTM (YoY)18.80%
Year-to-Date Return-25.32%
5-Day Price Return4.47%
EPS Normalized (Annual)$0.36
Month-to-Date Return4.47%
EBITD / Share (Annual)$-0.04
P/E Excl Extra (TTM)158.63x
EPS Basic Excl Extra (TTM)$0.20
P/B Ratio (Annual)1.33x
Book Value / Share (Annual)$8.03
Price vs S&P 500 (13W)-25.21%
Beta0.48x
Revenue / Share (TTM)$0.00
ROE (TTM)2.51%
52-Week Low$8.08
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.29
4.33
4.33
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BBOTBridgeBio Oncology Therapeutics, Inc. Common Stock | — | — | — | — | $9.26 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company developing cancer therapies that target RAS and PI3Ka mutations, two of the most frequently mutated oncogenic drivers. The company aims to address unmet needs in oncology by creating targeted treatments for patients with these genetically-driven cancers.